亚盛医药-B股价盘中涨超10%创年内新高，因Lisaftoclax潜力获进一步验证。该公司在ASCO年会公布其治疗肿瘤临床研究进展，且自与武田合作以来，股价累计涨幅达260%，市值突破190亿，2024年营收激增342%。
Source Link亚盛医药-B股价盘中涨超10%创年内新高，因Lisaftoclax潜力获进一步验证。该公司在ASCO年会公布其治疗肿瘤临床研究进展，且自与武田合作以来，股价累计涨幅达260%，市值突破190亿，2024年营收激增342%。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.